These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38428724)

  • 21. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
    Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD
    J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A modified HSV-1 oncolytic virus reconciles antiviral and antitumor immunity via promoting IFNβ expression and inhibiting PKR.
    Shen Y; Zhao X; Chen L; Wang X; Wang D; Zhang H; Zheng Z; Huang W; Zheng C; Chen Y; Chen C; Chen Q
    Int J Biol Macromol; 2024 Aug; 274(Pt 2):133297. PubMed ID: 38925170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor effects of IL-12 and GM-CSF co-expressed in an engineered oncolytic HSV-1.
    Kim KJ; Moon D; Kong SJ; Lee YS; Yoo Y; Kim S; Kim C; Chon HJ; Kim JH; Choi KJ
    Gene Ther; 2021 Apr; 28(3-4):186-198. PubMed ID: 33149278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity.
    Haines BB; Denslow A; Grzesik P; Lee JS; Farkaly T; Hewett J; Wambua D; Kong L; Behera P; Jacques J; Goshert C; Ball M; Colthart A; Finer MH; Hayes MW; Feau S; Kennedy EM; Lerner L; Quéva C
    Cancer Immunol Res; 2021 Mar; 9(3):291-308. PubMed ID: 33355229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic delivery of oncolytic herpes virus using CAR-T cells enhances targeting of antitumor immuno-virotherapy.
    Zhang Z; Yang N; Xu L; Lu H; Chen Y; Wang Z; Lu Q; Zhong K; Zhu Z; Wang G; Li H; Zheng M; Zhou L; Tong A
    Cancer Immunol Immunother; 2024 Jul; 73(9):173. PubMed ID: 38953982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy.
    Workenhe ST; Pol JG; Lichty BD; Cummings DT; Mossman KL
    Cancer Immunol Res; 2013 Nov; 1(5):309-19. PubMed ID: 24777969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumour-specific triple-regulated oncolytic herpes virus to target glioma.
    Delwar ZM; Liu G; Kuo Y; Lee C; Bu L; Rennie PS; Jia WW
    Oncotarget; 2016 May; 7(19):28658-69. PubMed ID: 27070093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells.
    Petrovic B; Leoni V; Gatta V; Zaghini A; Vannini A; Campadelli-Fiume G
    J Virol; 2018 Mar; 92(6):. PubMed ID: 29263257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generation and validation of recombinant herpes simplex type 1 viruses (HSV-1) using CRISPR/Cas9 genetic disruption.
    Bommareddy PK; Peters C; Kaufman HL
    Methods Enzymol; 2020; 635():167-184. PubMed ID: 32122544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer.
    Wang Q; Ma X; Wu H; Zhao C; Chen J; Li R; Yan S; Li Y; Zhang Q; Song K; Yuan C; Kong B
    Oncoimmunology; 2022; 11(1):2096362. PubMed ID: 35800156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incorporation of the B18R gene of vaccinia virus into an oncolytic herpes simplex virus improves antitumor activity.
    Fu X; Rivera A; Tao L; Zhang X
    Mol Ther; 2012 Oct; 20(10):1871-81. PubMed ID: 22692498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy.
    Ghonime MG; Cassady KA
    Cancer Immunol Res; 2018 Dec; 6(12):1499-1510. PubMed ID: 30352799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
    Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Construction of Oncolytic Herpes Simplex Virus with Therapeutic Genes of Interest.
    Kahramanian A; Kuroda T; Wakimoto H
    Methods Mol Biol; 2019; 1937():177-188. PubMed ID: 30706396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modification of HSV-1 to an oncolytic virus.
    Nakashima H; Chiocca EA
    Methods Mol Biol; 2014; 1144():117-27. PubMed ID: 24671680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltration.
    Liang Y; Wang B; Chen Q; Fu X; Jiang C; Lin Z; Zhuang Q; Zeng Y; Liu X; Zhang D
    Theranostics; 2023; 13(15):5452-5468. PubMed ID: 37908722
    [No Abstract]   [Full Text] [Related]  

  • 37. An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer.
    Tsuji T; Nakamori M; Iwahashi M; Nakamura M; Ojima T; Iida T; Katsuda M; Hayata K; Ino Y; Todo T; Yamaue H
    Int J Cancer; 2013 Jan; 132(2):485-94. PubMed ID: 22729516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor Tropism of DNA Viruses for Oncolytic Virotherapy.
    Enow JA; Sheikh HI; Rahman MM
    Viruses; 2023 Nov; 15(11):. PubMed ID: 38005938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Dilemma of HSV-1 Oncolytic Virus Delivery: The Method Choice and Hurdles.
    Tang G; Wang D; Zhao X; Feng Z; Chen Q; Shen Y
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The potential of swine pseudorabies virus attenuated vaccine for oncolytic therapy against malignant tumors.
    Wang G; Cao J; Gui M; Huang P; Zhang L; Qi R; Chen R; Lin L; Han Q; Lin Y; Chen T; He P; Ma J; Fu R; Hong J; Wu Q; Yu H; Chen J; Huang C; Zhang T; Yuan Q; Zhang J; Chen Y; Xia N
    J Exp Clin Cancer Res; 2023 Oct; 42(1):284. PubMed ID: 37891570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.